RxDoctor Payments Data

Katrina Horner

Family · Providence, RINPI 1699482182

Payments from drug & device makers

$1,936in general payments, 2019–2025

Across 25 payments — averaging $77.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$848
  • Dexcom, Inc.$283
  • Novo Nordisk$144
  • E.r. Squibb & Sons, L.L.C.$128
  • Medtronic$117
  • BETA Bionics, Inc.$100
  • plus $317 from 4 others

What the payments were for

  • Food & beverage$1,936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,936 in reported general payments places this provider in the 80th percentile of 457 family providers in Rhode Island.

See all family providers in Rhode Island

Medicare billing

Part B allowed, 2024
$3,773
Medicare patients
21
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$83,067
MounjaroTirzepatide54$63,106
JardianceEmpagliflozin50$42,318
TrulicityDulaglutide29$27,697
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/720$12,640
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$6,575
Humalog Kwikpen U-100Insulin Lispro20$5,210
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,844
Nano 2nd Gen Pen NeedlePen Needle, Diabetic22$1,891
Pregabalin33$1,479
Insulin Lispro16$1,174
Metformin Hcl ErMetformin Hcl68$714
Levothyroxine Sodium40$428
Atorvastatin Calcium57$346
Metformin Hcl19$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$97$91,97799 claims
Novo NordiskOzempic$144$83,06788 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 457 family providers in Rhode Island.

Other family in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →